High-nerve-targeting AAV (adeno-associated virus) capsid protein mutant and application thereof
By replacing the specific amino acid sequence of the AAV9 viral capsid protein, a highly neural targeted AAV viral capsid protein mutant was constructed, which solved the shortcomings of AAV9 gene therapy in terms of neural targeting and infection efficiency, and achieved higher viral yields and neural targeting performance.
Patent Information
- Application Number
- CN202411183011.8
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-08-27
- Publication Date
- 2024-11-29
AI Technical Summary
AAV9 gene therapy still has shortcomings in improving neurotargeting, dynamics and infection efficiency, and most mutant capsid proteins cannot assemble or package the genome, limiting the progress of capsid modification.
By replacing the amino acid sequence of AAV9 viral capsid protein 586-588, using sequences such as SDGTMEKPFR, QEGTMEKPFR, ANGTVDRPFK and GPQILKGYDI, a highly neural targeted AAV viral capsid protein mutant was constructed, and the corresponding expression system and recombinant AAV viral vector were constructed. .
The neural targeting and viral yield of AAV virus were significantly improved, and the problem of low expression efficiency after penetration of the blood-brain barrier was solved. The constructed recombinant AAV vector has good yield and neural targeting performance.
Smart Images

Figure CN119039402A_ABST
Abstract
Description
Technical Field
[0001] The present invention belongs to the field of biotechnology, and in particular relates to a variety of highly neural-targeted AAV virus capsid protein mutants and applications thereof. Background Art
[0002] Adeno-associated virus (AAV) is a delivery vector widely used in gene therapy. Its principle is to replace the sequence between the ITRs of the AAV genome with the target gene sequence through genetic engineering methods, and transmit it to the target cell through cell infection to achieve the purpose of gene therapy. Based on the characteristics of safety, high efficiency, stability, persistence, specificity, and low integration of recombinant AAV, AAV has become one of the main delivery methods in the field of gene therapy. At present, 12 human AAV serotypes (AAV1 to AAV12) have been discovered. Different AAV serotypes have different capsid protein spatial structures, sequences, and tissue specificity, so their recognition and binding cell surface receptors are very different, which leads to different tissue types, cell types, and infection efficiencies infected by different serotypes. Among them, the AAV9 serotype is increasingly used in gene therapy due to its strong neural tropism and ideal safety. However, AAV9 gene therapy still requires more disease molecular targets, and further research is still needed to improve the targeting of gene expression, the regulation of dynamics and effectiveness, release, and infection efficiency. Capsid engineering is a bottleneck in creating novel AAV capsids, as most mutant capsid proteins cannot assemble or package their genomes.
[0003] Based on the shortcomings of AAV vectors, researchers are using a series of methods to modify AAV, by modifying the genetic structure of the viral vector, expanding its vector capacity, improving the virus yield and the transfection efficiency of different tissue cells, so as to make AAV vectors more in line with the needs of different diseases. Summary of the invention
[0004] The object of the present invention is to overcome at least one deficiency of the prior art and to provide a variety of highly neural-targeted AAV virus capsid protein mutants and their applications.
[0005] The technical solution adopted by the present invention is: The first aspect of the present invention provides: A highly neural-targeted AAV viral capsid protein mutant was obtained by replacing amino acids 586-588 of the wild-type AAV9 viral capsid protein with SDGTMEKPFR, QEGTMEKPFR, ANGTVDRPFK, and GPQILKGYDI.
[0006] The second aspect of the present invention provides: A gene encoding the AAV virus capsid protein mutant described in the first aspect of the present invention.
[0007] The third aspect of the present invention provides: An expression system that expresses the AAV virus capsid protein mutant described in the first aspect of the present invention, or contains the gene described in the second aspect of the present invention.
[0008] The expression system may only express the AAV virus capsid protein mutant described in the first aspect of the present invention, and may be used in conjunction with a corresponding auxiliary expression system.
[0009] In some examples of expression systems, the expression system is a recombinant AAV vector, and the recombinant AAV vector is obtained by inserting or replacing an AAV vector.
[0010] In some examples of expression systems, the AAV is selected from any one of AAV1, AAV2, AAV3, AAV4, AAV5, AAV6, AAV7, AAV8, AAV9 or AAV10 and variants thereof.
[0011] In some examples of expression systems, the expression system further comprises a nucleic acid molecule encoding a functional gene product.
[0012] A fourth aspect of the present invention provides: A recombinant AAV virus, whose capsid protein is as shown in the first aspect of the present invention.
[0013] In some examples of recombinant AAV viruses, the AAV is selected from any one of AAV1, AAV2, AAV3, AAV4, AAV5, AAV6, AAV7, AAV8, AAV9 or AAV10 and variants thereof.
[0014] Other structural proteins of the recombinant AAV virus can be expressed by other auxiliary expression systems.
[0015] A fifth aspect of the present invention provides: A composition comprises the expression system and an acceptable vector described in the third aspect of the present invention, or the recombinant AAV virus described in the fourth aspect of the present invention.
[0016] A sixth aspect of the present invention provides: The fifth aspect of the present invention is the use of the composition in preparing gene therapy preparations or transgenic preparations targeting the central nervous system or constructing transgenic animals targeting the central nervous system.
[0017] In some application examples, the central nervous system is a cranial nerve.
[0018] The beneficial effects of the present invention are: The capsid protein mutants of some examples of the present invention can effectively improve the neural targeting of AAV virus and fundamentally solve the problem of expression efficiency of AAV9 after penetrating the blood-brain barrier.
[0019] The capsid protein mutants of some examples of the present invention can construct recombinant AAV virus vectors with good yield. BRIEF DESCRIPTION OF THE DRAWINGS
[0020] The present invention will be further described below with reference to the accompanying drawings and embodiments, wherein: Figure 1 to Figure 4 The agarose gel electrophoresis identification diagram of the mutant plasmid constructed in the test example of this invention.
[0021] Figure 5 Graph showing virus yield in an embodiment of the present invention.
[0022] Figure 6 This is a comparison of the expression levels of EGFP protein in the brain after tail vein injection of different AAV9 variants.
[0023] Figure 7 This is a comparison of the expression levels of EGFP protein in the cortex after tail vein injection of different AAV9 variants.
[0024] Figure 8 This is a comparison of the expression levels of EGFP protein in the hippocampus after tail vein injection of different AAV9 variants.
[0025] Fig. 9 This is a comparison of the expression levels of EGFP protein in the thalamus after tail vein injection of different AAV9 variants.
[0026] Fig.10 This is a comparison of the expression levels of EGFP protein in the striatum after tail vein injection of different AAV9 variants.
[0027] Fig.11 This is a comparison of the expression levels of EGFP protein in the liver after tail vein injection of different AAV9 variants.
[0028] Fig.12 This is a comparison of the expression levels of EGFP protein in the brain after lumbar intrathecal injection of different AAV9 variants.
[0029] Fig.13 This is a comparison of the expression levels of EGFP protein in the cortex after lumbar intrathecal injection of different AAV9 variants.
[0030] Fig.14 This is a comparison of the expression levels of EGFP protein in the hippocampus after lumbar intrathecal injection of different AAV9 variants.
[0031] Fig.15This is a comparison of the expression levels of EGFP protein in the thalamus after lumbar intrathecal injection of different AAV9 variants.
[0032] Fig.16 This is a comparison of the expression levels of EGFP protein in the striatum after lumbar intrathecal injection of different AAV9 variants.
[0033] Fig.17 This is a comparison of the expression levels of EGFP protein in the liver after lumbar intrathecal injection of different AAV9 variants. DETAILED DESCRIPTION
[0034] AAV variants generally refer to mutations in one or several amino acid sites based on a wild serotype of AAV, such as AAV2, AAV9, etc., such as deletion mutations, point mutations, insertion mutations, etc. The biological effects of AAV variants, such as virus production, infectivity, immunogenicity, etc., are somewhat different from those of the original AAV. The newly mutated amino acid sequence itself may have specific effects. For example, the common YF mutation can reduce the possibility of AAV being degraded by the proteasome and improve the infection effect of AAV (see Zhong L, Li B, Mah CS, et al. Next generation of adeno-associated virus 2 vectors: point mutations in tyrosines lead to high-efficiency transduction at lower doses[J]. Proceedings of the National Academy of Sciences, 2008, 105(22): 7827-7832.). Moreover, this characteristic is effective in different serotypes such as AAV2, AAV8, and AAV9 (see Petrs-Silva H, Dinculescu A, Li Q, et al. High-efficiency transduction of the mouse retina by tyrosine-mutant AAV serotype vectors[J]. Molecular therapy, 2009, 17(3): 463-471.). The specificity of AAV vectors is mainly determined by their capsid proteins. The same capsid proteins often exhibit the same or similar functions in different AAV vectors. Capsid proteins can also self-assemble with other AAV structural proteins to form a complete capsid and encapsulate genes.
[0035] The following will clearly and completely describe the concept of the present invention and the technical effects produced in combination with the embodiments, so as to fully understand the purpose, characteristics and effects of the present invention. Obviously, the described embodiments are only part of the embodiments of the present invention, not all of them. Based on the embodiments of the present invention, other embodiments obtained by technicians in this field without creative work are all within the scope of protection of the present invention. The test methods used in the embodiments are all conventional methods unless otherwise specified; the materials, reagents, etc. used, unless otherwise specified, can all be reagents and materials obtained from commercial channels.
[0036] Example 1 This example provides a variety of adeno-associated virus capsid protein mutants (AAV9-PM221 to PM240) based on NGS sequencing and previous studies, and the amino acid sequences of the replaced parts are shown in Table 1.
[0037] Table 1. Amino acid sequence information of AAV9-WT and its mutant Cap586-588 sequence name Sequence information serial number AAV9-WT-Cap586-588 SAQ 2 PM221 LQSTQCQVVG 3 PM222 LTSTQCQHVG 4 PM223 LTSTQCQVVG 5 PM224 LTSTQCQVVT 6 PM225 NAQSLCKRFV 7 PM226 PLQTQCQLVL 8 PM227 SDGTMEKPFR 9 PM228 QEGTMEKPFR 10 PM229 PVQTQCQLVL 11 PM230 QPQSGCYPVM 12 PM231 ANGTVDRPFK 13 PM232 QPQSVCYPVM 14 PM233 QPQSYCHPVM 15 PM234 SAQTQCQVFG 16 PM235 SAQTVCRNFV 17 PM236 SLPSVCRAFV 18 PM237 SSPSLCRSFV 19 PM238 SNQTDCRPFL 20 PM239 SSPSLCRAFV 21 PM240 GPQILKGYDI 22 The method for constructing an adeno-associated virus variant comprises the following steps: 1. Plasmid construction The nucleic acid sequence corresponding to the amino acid sequence of PM221 to PM240 (as shown in Table 1) was synthesized by gene synthesis, and the synthesized sequence was cloned into the pAAV9 plasmid by the existing method, and the amino acids 586-588 of CAP9 were replaced with the mutant sequence to construct the pAAV9-PM mutant plasmid vector; the ligation product was transformed into Escherichia coli competent cell Top10, and a single colony was picked to extract the plasmid for sequencing verification and restriction enzyme digestion verification, and the results were identified by agarose gel electrophoresis. Figure 1 to Figure 4 As shown, it indicates that the mutant plasmid was successfully constructed.
[0038] 2. Virus packaging and purification includes the following steps 2.1 Cell culture 2.1.1 Take out a tube of HEK293T cells from the liquid nitrogen tank, quickly put the cryotube into a 37℃ water bath, gently shake to thaw the cells quickly, centrifuge at 200×g for 5 min, discard the supernatant, resuspend in 10 ml DMEM+10% FBS complete medium, place in a 10 cm culture dish, and incubate at 37℃, 5% CO 2 Medium cultivation; 2.1.2 After 2-3 days of culture, when the cell confluence reaches about 80%, the cells can be subcultured; 2.1.3 Discard the culture supernatant, wash the cells once with 5 ml PBS buffer, add 1.5 ml TrypLESelect (1×) digestion solution, digest at 37℃ for 3-5 min, and add 4.5 ml DMEM complete medium to terminate the digestion; 2.1.4 Pipette cells to form a cell suspension, subculture at a ratio of 1:4-1:5, and inoculate into T300 flasks for culture.
[0039] 2.2 Cell transfection 2.2.1 After 2-3 passages, the cells are cultured for 48 hours and the cell confluence reaches 80%-90%, and the cells can be transfected; 2.2.2 Each bottle of cells is transfected as one group. Take 1 mL of serum-free DMEM medium into a centrifuge tube, add packaging plasmid, pHelper, and pAAV-CAG-EGFP expression plasmid (total 60 μg) in sequence, mix well, and let stand for 5 minutes. This is the "plasmid dilution solution"; 2.2.3 Take another 1 ml of DMEM medium and put it into a new centrifuge tube, add 180 ug PEI and mix well, let it stand for 5 minutes, which is the "PEI dilution solution"; 2.2.4 Pour the "PEI diluent" into the "plasmid diluent", mix quickly, and let stand at room temperature for 25-30 minutes to form a transfection complex; add the transfection complex to 80 ml DMEM culture medium and shake gently to mix; 2.2.5 Take out the T300 cell culture flask, discard the culture supernatant, and add the culture medium containing the transfection complex; 2.2.6 At 37°C, 5% CO 2 Medium cultivation.
[0040] 2.3 Virus harvest 2.3.1 After transfection, cells were cultured for 72 hours and virus harvesting was started; 2.3.2 Mix the culture supernatants of each group and collect them in a centrifuge bottle. Centrifuge at 200g for 5 min and collect the supernatant. Add 0.245 mL of 50% PEG8000 solution (containing 0.5 mol / L NaCl) to each mL of supernatant, mix thoroughly, and let stand at 2-8°C overnight. 2.3.3 Add 5 ml of 0.5% TritonX-100 cell lysis buffer (containing universal nuclease) to the cells in the culture flask, treat at 37°C for 1-2 h, then add 0.55 ml of 5 mol / L NaCl to a final concentration of 0.5 mol / L, mix thoroughly, centrifuge at 4°C, 3000 g for 15 min, collect the supernatant, and temporarily store at 2-8°C; 2.3.4 Centrifuge the supernatant after PEG8000 precipitation at 4℃, 3000g for 15 min, remove the supernatant, add 2ml 0.5% TritonX-100 cell lysis buffer (containing universal nuclease), treat at 37℃ for 1-2 h, then add 0.22ml 5mol / L NaCl to a final concentration of 0.5 mol / L, mix thoroughly, centrifuge at 3000g for 15 min, and collect the supernatant. Combine the supernatant in step 2.3.3 with it in a centrifuge tube, which is the "viral crude extract".
[0041] 2.4 Virus purification 2.4.1 Take an ultracentrifuge tube and use a stainless steel needle to slowly add 15 ml of "virus crude extract", 9 ml of 15% iodixanol, 6 ml of 25% iodixanol, 5 ml of 40% iodixanol and 5 ml of 60% iodixanol from the bottom of each ultracentrifuge tube; balance and seal with cell lysis buffer; 2.4.1 Ultracentrifuge, 340,000 g, 16°C, centrifuge for 2 h; 2.4.3 Take an ultrafiltration tube and soak the filter membrane with 4 mL PBS buffer; 2.4.4 Carefully extract the 40% Iodixanol-60% Iodixanol intermediate layer from the ultracentrifuge tube using a syringe and transfer it to an ultrafiltration tube; 2.4.5 Add appropriate amount of PBS buffer and pipette evenly, centrifuge at 3000 g for 3-5 min, and repeat at least 5 times to remove iodixanol; 2.4.6 Add 1 mL PBS buffer and pipette 40-50 times to form a virus suspension, then transfer to an EP tube; 2.4.7 Use a 1 mL syringe to draw the virus suspension in the EP tube and filter it through a 0.22 μm filter. After collecting 20 μL of the virus solution as the test sample, the remaining virus was dispensed into 100 μL tubes to obtain the pAAV-CAG-EGFP virus library.
[0042] 3. Virus yield detection 3.1 Virus Lysis Take 20 μL of the virus library sample, add 1 μL of 10% SDS, 0.5 mol / L EDTA, and proteinaseK respectively, and mix well; incubate at 56°C for 1 hour, and then incubate at 90°C for 10 min; dilute the lysed virus sample 1000 times to obtain the "virus dilution solution" 3.2 PCR amplification Use the "virus dilution" in step (1) as a DNA template, and mix with Q5 high-fidelity mixture, forward primer 5'-cggagtcctatggacaagtggccacaaaccaccag-3' (SEQID NO.24:), reverse primer 5'-ccttggttttgaacccagccggtctgcgcctgt-3' (SEQID NO.25:) and deionized water according to the sample loading system in Table 2. The PCR reaction program is: 98℃, 3 min, 1 cycle; 98℃, 15 s, 60℃, 20 s, 72℃, 24 s, 25 cycles; 72℃, 2 min, 1 cycle.
[0043] Table 2. PCR amplification sample addition system Reagent name Add volume Q5 High-Fidelity 2X Master Mix 25 µl 10 µM Forward Primer (SEQ ID NO.24) 2.5 µl 10 µM Reverse Primer (SEQ ID NO.25) 2.5 µl Template DNA 10 µl Enzyme-free water Add to 50 µl 3.3 PCR product gel recovery The PCR product was subjected to 2% agarose gel electrophoresis and observed with a gel imaging system. The gel block with the correct band was cut and recovered with a gel recovery kit. The AAV genome copy number was detected by qPCR to obtain the yield result, such as Figure 5 As shown, PM227 to PM232, as well as PM239 and PM240, had significantly better yields than wild-type AAV9. These high-yield AAV variants were subsequently tested for neural targeted infection.
[0044] Comparative Example 1 This comparative example provides a wild-type adeno-associated virus (AAV9-WT), which is prepared according to the preparation method of Example 1 with respect to the AAV9 mutant, and the only difference between them is that the sequence of the adeno-associated virus capsid protein adopts the wild-type AAV9 capsid protein sequence.
[0045] Comparative Example 2 This comparative example provides an AAV9 adeno-associated virus mutant (AAV-PHP.eB) that has been verified to have good neural targeting in animal experiments. It is prepared according to the preparation method of Example 1 with the AAV9- mutant, and the only difference is that the adeno-associated virus capsid protein sequence adopts the mutant AAV-PHP.eB capsid protein sequence (SEQ ID NO.23).
[0046] Test Example 1: Mouse nerve targeted infection performance test 1. Virus injection The AAV-CAG-EGFP virus library was obtained and injected into the tail vein. Each mouse was injected with 5E9 VG virus (volume 200 µl), fed normally, and the survival was observed every day.
[0047] 2. Obtain materials 2.1 Fix the anesthetized mouse, cut the skin horizontally under the mediastinum to expose the internal organs, cut horizontally on the left and right sides to fully expose; cut the chest diaphragm to quickly expose the heart, fix the heart with the thumb and index finger of the left hand, insert the perfusion needle from the apex of the heart, enter the aorta through the left ventricle, fix the perfusion needle with a vascular clamp, and cut the right ventricle; 2.2. First, infuse with 0.9% saline, about 200 ml (50 ml syringe push, quickly); then infuse with 4% paraformaldehyde, and adjust the flow rate with the infusion device, quickly for the first 100 ml and slowly for the next 150 ml; 2.3 Decapitation of the brain, opening of the abdomen to remove the liver, and immersion of the brain and liver tissues in 4% paraformaldehyde for 24 h; 2.4 Immerse the brain and liver tissues in 20% sucrose until the tissues sink to the bottom for 2 days (change the sucrose every day); 2.5 Immerse the brain and liver tissues in 30% sucrose until the tissues sink to the bottom for 2 days (change the sucrose every day); 2.6 Remove the brain and liver tissues, trim them according to the required brain area or liver (refer to the mouse atlas for positioning), fix them on the stage with OCT glue, and quickly freeze them at -70℃; perform coronal sectioning (slice thickness 10 μm) on a freezing microtome, and immediately rinse the cut slices three times with 0.01M PBS; attach the slices flatly on a glass slide, drop 10 μl of anti-fluorescence quencher containing DAPI on each slice, cover the slices with a coverslip, and photograph them under a fluorescence microscope.
[0048] The results are as follows Figure 6 to Figure 11 As shown, after tail vein injection of PM227, PM228, and PM231, the EGFP fluorescence intensity expressed in the brain was significantly better than that of wild-type AAV9, and PM228 was better than PHP.eB; after tail vein injection of PM227, PM228, PM230, PM231, and PM232, the EGFP fluorescence intensity expressed in the liver was significantly lower than that of wild-type AAV9.
[0049] Test Example 2: Mouse nerve targeted infection performance test 1. Virus injection The AAV-CAG-EGFP virus library was obtained and injected intrathecally at the lumbar spine. Each mouse was injected with 3E10 VG viruses (volume 20 µl), and the mice were fed conventionally and their survival was observed every day.
[0050] 2. The material collection and film production process are the same as test example 1.
[0051] The results are as follows Figures 12 to 17 As shown, the EGFP fluorescence intensity expressed in the brain of PM240 after lumbar intrathecal injection was significantly higher than that of wild-type AAV9; the EGFP fluorescence intensity expressed in the liver of PM239 and PM240 after lumbar intrathecal injection was significantly lower than that of wild-type AAV9.
[0052] The difference between the sequences PM227, PM228, PM231, and PM240 of the variant capsid proteins of adeno-associated virus and the wild-type AAV9 capsid protein is that the amino acid sequences 586 to 588 of the wild-type capsid protein are replaced by the amino acid sequences of PM227, PM228, PM231, and PM240 (as shown in SEQ ID NO.9, SEQ ID NO.10, SEQ ID NO.13, and SEQ ID NO.22). The amino acid sequence of the wild-type adeno-associated virus capsid protein CAP9 is shown in SEQ ID NO.1 (GenBank: AAS99264.1).
[0053] In summary, the adeno-associated virus variant prepared by the scheme of the present invention can significantly enhance the neural targeted infection performance of AAV9 virus compared with the wild type.
[0054] Amino acid sequence of wild-type AAV9 adeno-associated virus capsid protein CAP9: MAADGYLPDWLEDNLSEGIREWWALKPGAPQPKANQQHQDNARGLVLPGYKYLGPGNGLDKGEPVNAADAAALEHDKAYDQQLKAGDNPYLKYNHADAEFQERLKEDTSFGGNLGRAVFQAKKRLLEPLGLVEEAAKTAPGKKRPVEQSPQEPDSSAGIGKSGAQPAKKRLNFGQTGDTESVPDPQPIGEPPAAPSGVGSLTMASGGGAPVADNNEGADGVGSSSGNWHCDSQWLGDRVITTSTRTWALPTYNNHLYKQISNSTSGGSSNDNAYFGYSTPWGYFDFNRFHCHFSPRDWQRLINNNWGFRPKRLNFKLFNIQVKEVTDNNGVKTIANNLTSTVQVFTDSDYQLPYVLGSAHEGCLPPFPADVFMIPQYGYLTLNDGSQAVGRSSFYCLEYFPSQMLRTGNNFQFSYEFENVPFHSSYAHSQSLDRLMNPLIDQYLYYLSKTINGSGQNQQTLKFSVAGPSNMAVQGRNYIPGPSYRQQRVSTTVTQNNNSEFAWPGASSWALNGRNSLMNPGPAMASHKEGEDRFFPLSGSLIFGKQGTGRDNVDADKVMITNEEEIKTTNPVATESYGQVATNHQSAQAQAQTGWVQNQGILPGMVWQDRDVYLQGPIWAKIPHTDGNFHPSPLMGGFGMKHPPPQILIKNTPVPADPPTAFNKDKLNSFITQYSTGQVSVEIEWELQKENSKRWNPEIQYTSNYYKSNNVEFAVNTEGVYSEPRPIGTRYLTRNL(SEQ ID NO.1) Amino acid sequence of the AAV9 adeno-associated virus mutant capsid protein CAP9-AAV-PHP.eB: MAADGYLPDWLEDNLSEGIREWWALKPGAPQPKVSLWDPCFLSPSFLWLSSCHRKGISNRVQFRMGNRRMIASVWKSQDRFSFFYLLFITIVFFCLILAFFFFLLRNFYYYTCLNIVYNKRKYLDTLSNLKKNFTQSAYITIWNICVLICIFIISLLYFLLFLIDTSLYIFMGSVMFYVYTYPNQGNFAFVILKNAFFFYTFLFILFLILSLISFFQGNNDTMYHASLHHSKEQFLGGNSNISAYKYFCIIVTDVRGFILLIAATIQLPFCFYFMVGIRLDYSESKLGPFANHVHTSYLPPTGKSTTSRQRSRSCASGLQIPWTRQRTRQGGAGQRSRRGGPRARQGLRPAAQGRRQPVPQVQPRRRRVPGAAQRRYVFWGQPRASSLPGQKEASTSWSGGSGDGSWKEEACRAVSSGTGLLRGYWQIGCTARKETQFRSDWRHRVSPRPSTNRRTSRSPLRCGISYNGFRWWRTSGRQRRCRWSGFLGKLALRFPMAGGQSHHHQHPNLGPAHLQQSPLQANLQQHIWRIFKQRLLRLQHPLGVFLQQIPLPLLTTLAATHQQQLGIPAATQLQALQHSGQRGYGQQWSQDHRQPYQHGPGLHGLRLSAPVRARVGSRGLPPAVPSGRFHDSSVRVSDAWKPGRGSFVLLLPGIFPVANAKNGQLPVQLRVERTFPQLRSQPKPGPTNESTHRPILVLSLNYRFWTESTNAKIQCGRTQQHGCPGKKLHTWTQLPTTTCLNHCDSKQQQRICLAWSFFLGSQWTLDESWTCYGQPQRRRGPFLSFVWIFNFWQTRYRQRQRGCGQSHDNQRRRNNYPGSNGVLWTSGHKPPEWDFGGAFGTGADRLGSKPRNTSGYGLAGQRCVPARTHLGQNSSHGRQLSPFSADGRVWNEAPASSDPHQKHTCTCGSSNGLQQGQAELFHHPVFYWPSQRGDRVGAAEGKQQALEPGDPVHFQLLQVCICCYRCITPPHWHQIPDSSV(SEQ ID NO.23)。
[0055] The above is a further detailed description of the present invention, which should not be regarded as a limitation on the specific implementation of the present invention. For ordinary technicians in the technical field to which the present invention belongs, simple deduction or replacement without departing from the concept of the present invention is within the protection scope of the present invention.
Claims
1. A highly neuro-targeted AAV virus capsid protein mutant, characterized in that: It is obtained by replacing the amino acids 586-588 of the wild-type AAV9 virus capsid protein with SDGTMEKPFR, QEGTMEKPFR, ANGTVDRPFK, and GPQILKGYDI.
2. A gene encoding the AAV virus capsid protein mutant according to claim 1.
3. An expression system, characterized in that It expresses the AAV virus capsid protein mutant described in claim 1, or contains the gene described in claim 2.
4. The expression system according to claim 3, characterized in that The expression system is a recombinant AAV vector, and the recombinant AAV vector is obtained by inserting or replacing the AAV vector.
5. The expression system according to claim 4, characterized in that The AAV is selected from any one of AAV1, AAV2, AAV3, AAV4, AAV5, AAV6, AAV7, AAV8, AAV9 or AAV10 and variants thereof.
6. The expression system according to claim 3, characterized in that The expression system also includes a nucleic acid molecule encoding a functional gene product.
7. A recombinant AAV virus, characterized in that The capsid protein is as shown in claim 1.
8. The recombinant AAV virus according to claim 7, characterized in that The AAV is selected from any one of AAV1, AAV2, AAV3, AAV4, AAV5, AAV6, AAV7, AAV8, AAV9 or AAV10 and variants thereof.
9. A composition comprising the expression system according to any one of claims 3 to 6 and an acceptable vector, or the recombinant AAV virus according to claim 7 or 8.
10. The use of the composition according to claim 9, wherein the use is selected from: Preparation of gene therapy preparations or transgenic preparations targeting the central nervous system; Construction of transgenic animals targeting the central nervous system.
